Share Twitter LinkedIn Facebook Email Jalaja Potluri, MD of AbbVie Inc. discusses what’s next for her study and her hopes for the drug to become FDA approved. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Advances in Acute Lymphoblastic Leukemia (ALL) Treatment: A Focus on Targeted Therapies – Elias Jabbour, MD Acute Lymphoblastic Leukemia 4 Mins Read
FDA grants accelerated approval to ponatinib (ICLUSIG®) with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia Acute Lymphoblastic Leukemia 3 Mins Read
FDA Approves Inotuzumab Ozogamicin (BESPONSA) for Acute Lymphoblastic Leukemia in Pediatric Patients [Exclusive Video] Acute Lymphoblastic Leukemia 3 Mins Read